Furthermore, administration of additional IFNα and CXCL10 may be a candidate tumor treatment for CD8+ T cell-specific recruitment to enhance the efficacy of anti-PD-(L)1 immunotherapy and improve clinical outcomes for patients with various cancers. Here, CXCL10 is linked to neoplasm.